NCT07219212

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Johnson & Johnson Enterprise Innovation Inc. · Industry
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).

Conditions

• Squamous Cell Carcinoma of Head and Neck

Interventions

Type	Name	Description
DRUG	JNJ-90301900	JNJ-90301900 will administered via intratumoral and/or intranodal injection.
DRUG	Cisplatin	Cisplatin will be administered intravenously.
RADIATION	Intensity Modulated Radiation Therapy (IMRT)	IMRT radiation therapy will be administered.

Timeline

• Start date: 2026-01-26
• Primary completion: 2028-07-14
• Completion: 2028-07-14
• First posted: 2025-10-21
• Last updated: 2026-04-13

Locations

12 sites across 3 countries: United States, France, Japan

Regulatory

• FDA-regulated drug study